DOCSLIB.ORG

Global Report for Research on Infectious Diseases of Poverty 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Report for Research on Infectious Diseases of Poverty 2012 global reporT for research on infectious diseases of poverty 2012 wiTh financial supporT of European Union global report for research on infectious diseases of poverty with financial support of European Union WHo library Cataloguing-in-publication Data: Global report for research on infectious diseases of poverty. 1.communicable disease control. 2.research 3.poverty. 4.health behavior. 5.developing countries. i.World health organiza- tion. ii.unicef/undp/World Bank/Who special programme for research and training in tropical diseases. isBn 978 92 4 156 448 9 (nLM classification: aW 110) Copyright © World Health organization on behalf of the Special programme for research and training in tropical Diseases 2012 all rights reserved. the use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. a copy of any resulting product with such content should be sent to tdr, World health organization, avenue appia, 1211 Geneva 27, switzerland. tdr is a World health organi- zation (Who) executed unicef/undp/World Bank/World health organization special programme for research and training in tropical diseases. this information product is not for sale. the use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. no elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever. the designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of Who, including tdr, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its au- thorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by Who, including tdr, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted. photos: Who/tdr photo library; Ministério da saúde, Brasil; un photo library Graphic design: Lisa schwarb, Lausanne, switzerland printing: Who document production services, Geneva, switzerland Table of Contents Foreword ............................................................................................... 1 How tHe report was developed ................................................... 3 acknowledgements ........................................................................... 5 abbreviations ........................................................................................ 6 summary .................................................................................................. 9 Introduction 1. Why researcH inFectious diseases oF poverty? ............................. 10 Poverty and infectious disease – a problematic relationship ................ 12 Infectious disease – the true burden on communities ............................ 13 The value of research: new ways to end old diseases .............................. 15 Poverty, infectious disease and policy: moving beyond the Millennium Development Goals ............................... 15 The cost of inaction – social and economic consequences ..................... 18 Tackling disease – a need for investment .................................................... 19 Ten reasons to research infectious diseases of poverty .......................... 19 1. Break the vicious cycle of poverty and infectious disease ............................... 22 2. Forge an escape for the poor and vulnerable ................................................ 24 3. Tackle multiple problems ............................................................................ 26 4. Commute the life sentence .......................................................................... 28 5. Be prepared – forewarned is forearmed ........................................................ 30 Global Report for Research on Infectious Diseases of Poverty 6. Reach the hardest to reach .......................................................................... 33 7. Prevent loss in translation ........................................................................... 34 8. Identify small changes that can make a big difference .................................. 35 9. Stay focused on the light at the end of the tunnel ......................................... 36 10. Act quickly on what we know .................................................................... 38 Under the lens… ................................................................................................. 39 References – Chapter one ............................................................................... 40 i 2. environment, Climate change, SoCial FaCtorS anD tHe impliCationS For Controlling inFeCtiouS DiSeaSeS oF poverty ............................................................. 45 understanding the microbial world – the inescapable starting point ............................................................... 47 Drug and insecticide resistance – magic bullets will not suffice ......................... 48 Climate change – not entirely to blame ........................................................... 49 Deforestation – cutting the branch we sit on .................................................... 50 Urbanization – is wealthier always healthier? .................................................. 51 Agriculture – also sowing seeds of sickness ...................................................... 52 Hunger and malnutrition – getting the right food to the right table .................. 54 Conflict – another man-made disaster, amplifying infectious disease ................ 54 Migration and globalization – disease, a worldwide traveller ............................ 55 infectious diseases, the environment and poverty – a time bomb in the making? ........................................................................... 56 approaches for future research – three tracks to explore ...................... 57 Intorduction Better understanding of the microbial world ................................................... 58 Expand and better utilize existing data and resources ...................................... 58 “ One World, One Health”................................................................................ 59 overty p conclusion: a big picture requiring intelligent investment and interaction .................................................................................................. 61 iseases of references – chapter two ............................................................................... 62 d nfectious i 3. HealtH SyStemS .............................................................................................. 68 understanding the relationship between health esearch on r systems and diseases control programmes and the role of health systems research ............................................................. 70 Leadership and governance – getting a grip on things ..................................... 72 eport for r Financing – the right level at the right time and place ...................................... 74 Human resources for health – caring comes from people .................................. 76 Global Medicines and technology – an essential combination ..................................... 78 Health information and health infrastructure – good data clear the path .......... 79 Communities and health systems – people make the difference ........................ 80 Infectious diseases, poverty, health systems and health systems research – bringing it all together ................................................................................... 81 Developing the interface between health system components and infectious disease control programmes – the missing link ..................... 83 Developing systemic approaches .................................................................... 84 Strengthening research capacity for a positive interrelation between disease control programmes and the rest of the health system ..................................... 86 conclusions – from dependence to ownership .......................................... 87 references –chapter three ............................................................................. 89 ii table of contents 4. innovation anD neW technologieS to taCkle inFeCtiouS DiSeaSeS oF poverty ..................................................................................... 94 understanding the health innovation system – navigating unchartered waters ..................................................................... 96 Global initiatives to encourage innovation – turbo-charging ................ 98 funding for innovation – food for brains .................................................... 99 priority setting for health r&D – where to start? .................................... 101 policy environments in developing countries – more than scaffolding required ................................................................... 102 public–private product development
Load more

Recommended publications
  • Mathematical Model of the Role of Asymptomatic Infection in Outbreaks of Some Emerging Pathogens
    Tropical Medicine and Infectious Disease Article Mathematical Model of the Role of Asymptomatic Infection in Outbreaks of Some Emerging Pathogens Nourridine Siewe 1,* , Bradford Greening, Jr. 2 and Nina H. Fefferman 3 1 School of Mathematical Sciences, Rochester Institute of Technology, College of Sciences, 1 Lomb Memorial Dr, Rochester, NY 14623, USA 2 Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA; [email protected] 3 Department of Ecology and Evolutionary Biology, College of Sciences, The University of Tennessee, 447 Hesler, 569 Dabney Hall, 1416 Circle Dr, Knoxville, TN 37996-1610, USA; [email protected] * Correspondence: [email protected] Received: 1 October 2020; Accepted: 1 December 2020; Published: 9 December 2020 Abstract: Preparation for outbreaks of emerging infectious diseases is often predicated on beliefs that we will be able to understand the epidemiological nature of an outbreak early into its inception. However, since many rare emerging diseases exhibit different epidemiological behaviors from outbreak to outbreak, early and accurate estimation of the epidemiological situation may not be straightforward in all cases. Previous studies have proposed considering the role of active asymptomatic infections co-emerging and co-circulating as part of the process of emergence of a novel pathogen. Thus far, consideration of the role of asymptomatic infections in emerging disease dynamics have usually avoided considering some important sets of influences. In this paper, we present and analyze a mathematical model to explore the hypothetical scenario that some (re)emerging diseases may actually be able to maintain stable, endemic circulation successfully in an entirely asymptomatic state.
    [Show full text]
  • Endo, Backward Contact Tracing, WOR, 2020.Pdf
    Wellcome Open Research 2020, 5:239 Last updated: 03 NOV 2020 RESEARCH ARTICLE Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreaks [version 1; peer review: 2 approved] Akira Endo 1-3, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Quentin J. Leclerc 1,3, Gwenan M. Knight 1,3, Graham F. Medley 3,4, Katherine E. Atkins 1,3,5, Sebastian Funk 1,3, Adam J. Kucharski1,3 1Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK 2The Alan Turing Institute, London, NW1 2DB, UK 3Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK 4Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK 5Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, EH16 4UX, UK v1 First published: 13 Oct 2020, 5:239 Open Peer Review https://doi.org/10.12688/wellcomeopenres.16344.1 Latest published: 13 Oct 2020, 5:239 https://doi.org/10.12688/wellcomeopenres.16344.1 Reviewer Status Abstract Invited Reviewers Introduction: Contact tracing has the potential to control outbreaks without the need for stringent physical distancing policies, e.g. civil 1 2 lockdowns. Unlike forward contact tracing, backward contact tracing identifies the source of newly detected cases. This approach is version 1 particularly valuable when there is high individual-level variation in 13 Oct 2020 report report the number of secondary transmissions (overdispersion). Methods: By using a simple branching process model, we explored 1.
    [Show full text]
  • Infectious Diseases of Poverty, the First Five Years
    Wang et al. Infectious Diseases of Poverty (2017) 6:96 DOI 10.1186/s40249-017-0310-6 EDITORIAL Open Access Infectious Diseases of Poverty, the first five years Wei Wang1,2,3,4, Jin Chen5,6,7, Hui-Feng Sheng5,6,7, Na-Na Wang8, Pin Yang5,6,7*, Xiao-Nong Zhou5,6,7 and Robert Bergquist9 Abstract Although the focus in the area of health research may be shifting from infectious to non-communicable diseases, the infectious diseases of poverty remain a major burden of disease of global health concern. A global platform to communicate and share the research on these diseases is needed to facilitate the translation of knowledge into effective approaches and tools for their elimination. Based on the “One health, One world” mission, a new, open- access journal, Infectious Diseases of Poverty (IDP), was launched by BioMed Central in partnership with the National Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and Prevention (China CDC) on October 25, 2012. Its aim is to identify and assess research and information gaps that hinder progress towards new interventions for a particular public health problem in the developing world. From the inaugural IDP issue of October 25, 2012, a total of 256 manuscripts have been published over the following five years. Apart from a small number of editorials, opinions, commentaries and letters to the editor, the predominant types of publications are research articles (69.5%) and scoping reviews (21.5%). A total of 1 081 contributing authors divided between 323 affiliations across 68 countries, territories and regions produced these 256 publications.
    [Show full text]
  • Evolution of Clinical Trials Throughout History
    Evolution of clinical trials throughout history Emma M. Nellhaus1, Todd H. Davies, PhD1 Author Affiliations: 1. Office of Research and Graduate Education, Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Todd H. Davies, PhD Director of Research Development and Translation Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract The history of clinical research accounts for the high ethical, scientific, and regulatory standards represented in current practice. In this review, we aim to describe the advances that grew from failures and provide a comprehensive view of how the current gold standard of clinical practice was born. This discussion of the evolution of clinical trials considers the length of time and efforts that were made in order to designate the primary objective, which is providing improved care for our patients. A gradual, historic progression of scientific methods such as comparison of interventions, randomization, blinding, and placebos in clinical trials demonstrates how these techniques are collectively responsible for a continuous advancement of clinical care. Developments over the years have been ethical as well as clinical. The Belmont Report, which many investigators lack appreciation for due to time constraints, represents the pinnacle of ethical standards and was developed due to significant misconduct. Understanding the history of clinical research may help investigators value the responsibility of conducting human subjects’ research. Keywords Clinical Trials, Clinical Research, History, Belmont Report In modern medicine, the clinical trial is the gold standard and most dominant form of clinical research.
    [Show full text]
  • U.S. Investments in Medical and Health Research and Development 2013 - 2017 Advocacy Has Helped Bring About Five Years of Much-Needed Growth in U.S
    Fall 2018 U.S. Investments in Medical and Health Research and Development 2013 - 2017 Advocacy has helped bring about five years of much-needed growth in U.S. medical and health research investment. More advocacy is critical now to ensure our nation steps up in response to health threats that we can—we must—overcome. More Than Half Favor Doubling Federal Spending on Medical Research Do you favor or oppose doubling federal spending on medical research over the next five years? 19% Not Sure 23% 8% Strongly favor Strongly oppose 16% 35% Somewhat oppose Somewhat favor Source: A Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in January 2018. Research!America 3 Introduction Investment1 in medical and health research and development (R&D) in the U.S. grew by $38.8 billion or 27% from 2013 to 2017. Industry continues to invest more than any other sector, accounting for 67% of total spending in 2017, followed by the federal government at 22%. Federal investments increased from 2016 to 2017, the second year of growth after a dip from 2014 to 2015. Overall, federal investment increased by $6.1 billion or 18.4% from 2013 to 2017, but growth has been uneven across federal health agencies. Investment by other sectors, including academic and research institutions, foundations, state and local governments, and voluntary health associations and professional societies, also increased from 2013 to 2017. Looking ahead, medical and health R&D spending is expected to move in an upward trajectory in 2018 but will continue to fall short relative to the health and economic impact of major health threats.
    [Show full text]
  • Clinical Research Services
    Clinical Research Services Conducting efficient, innovative clinical research from initial planning to closeout WHY LEIDOS LIFE SCIENCES? In addition to developing large-scale technology programs for U.S. federal f Leidos has expertise agencies with a focus on health, Leidos provides a broad range of clinical supporting all product services and solutions to researchers, product sponsors, U.S. government development phases agencies, and other biomedical enterprises, hospitals, and health systems. for vaccines, drugs, and Our broad research experience enables us to support programs throughout biotherapeutics the development life cycle: from concept through the exploratory, f Leidos understands the development, pre-clinical, and clinical phases, as well as with product need to control clinical manufacturing and launching. Leidos designs and develops customized project scope, timelines, solutions that support groundbreaking medical research, optimize business and cost while remaining operations, and expedite the discovery of safe and effective medical flexible amidst shifting products. We apply our technical knowledge and experience in selecting research requirements institutions, clinical research organizations, and independent research f Leidos remains vendor- facilities to meet the specific needs of each clinical study. We also manage neutral while fostering and team integration, communication, and contracts throughout the project. managing collaborations Finally, Leidos has a proven track record of ensuring that research involving with
    [Show full text]
  • Diseases of Poverty and the 10/90 Gap
    4 Diseases of poverty and the 10/90 Gap Philip Stevens Introduction: What is the 10/90 Gap? Activists claim that only 10 per cent of global health research is devoted to conditions that account for 90 per cent of the global disease burden – the so-called ‘10/90 Gap’ (Medecins Sans Frontiers, 2001). They argue that virtually all diseases prevalent in low income countries are ‘neglected’ and that the pharmaceutical industry has invested almost nothing in research and development (R&D) for these diseases. Citing this alleged imbalance as justification, activists have for some years been calling for a complete redesign of the current R&D paradigm in order to ensure that more attention is paid to these ‘neglected diseases’ (Love & Hubbard, 2003). This could include measures such as an ‘essential research obligation’ that would require companies to reinvest a percentage of pharmaceutical sales into R&D for neglected diseases, either directly or through public R&D programs (Medecins Sans Frontiers, 2001), or the creation of a new public entity to direct R&D. This topic is now under discussion by a World Health Organisation working group following the report of its Commission on Intellectual Property, Innovation and Public Health.1 But does such an imbalance really exist and what would be the effect of redesigning the R&D system? This chapter investigates the realities of the 10/90 gap and its relation to the diseases of poverty. Diseases of poverty and the 10/90 gap 127 Neglected diseases Many scholars and activists have suggested that because there is little market for treatments for tropical infectious diseases such as leishmaniasis, lymphatic filariasis, Chagas’ disease, leprosy, Guinea worm, onchocerciasis and schistosomiasis, there is a consequent lack of suitable drugs.
    [Show full text]
  • The Failure of R0
    Hindawi Publishing Corporation Computational and Mathematical Methods in Medicine Volume 2011, Article ID 527610, 17 pages doi:10.1155/2011/527610 Review Article The Failure of R0 Jing Li,1 Daniel Blakeley,2 and Robert J. Smith?3 1 Department of Mathematics, Pennsylvania State University, University Park, State College, PA 16802, USA 2 School of Mathematics and Statistics, University of Sheffield, Hicks Building, Hounsfield Road, Sheffield S3 7RH, UK 3 Department of Mathematics and Faculty of Medicine, The University of Ottawa, 585 King Edward Avenue, Ottawa ON, Canada K1N 6N5 Correspondence should be addressed to Robert J. Smith?, [email protected] Received 30 January 2011; Revised 18 May 2011; Accepted 18 May 2011 Academic Editor: Haitao Chu Copyright © 2011 Jing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The basic reproductive ratio, R0, is one of the fundamental concepts in mathematical biology. It is a threshold parameter, intended to quantify the spread of disease by estimating the average number of secondary infections in a wholly susceptible population, giving an indication of the invasion strength of an epidemic: if R0 < 1, the disease dies out, whereas if R0 > 1, the disease persists. R0 has been widely used as a measure of disease strength to estimate the effectiveness of control measures and to form the backbone of disease-management policy. However, in almost every aspect that matters, R0 is flawed. Diseases can persist with R0 < 1, while diseases with R0 > 1 can die out.
    [Show full text]
  • 1 Why Research Infectious Diseases of Poverty?
    1 Why research infectious diseases of poverty? 11 in chapteR 1: • Poverty and infectious disease – a problematic relationship • infectious disease – the true burden on communities • the value of research: new ways to end old diseases • moving beyond the Millennium Development Goals • the cost of inaction – social and economic consequences • tackling disease – a need for investment • ten reasons to research infectious diseases of poverty AUTHORS Research is the key to making things Professor SiAn GRiffiths happen for poor populations. This Director, School of Public Health introductory chapter of the Global and Primary Care, The ChineSe Report examines the need for research univerSity of Hong Kong, Hong into the infectious diseases that Kong SPecial AdminiStrative region, China disproportionately affect poor and marginalized communities – the so- Professor Xiao-NonG Zhou Director, National InStitute called “infectious diseases of poverty”. of ParaSitic DiSeaSeS, ChineSe It examines the link between poverty center for DiSeaSe Control anD and disease and outlines ten reasons Prevention, Shanghai, China to support research for such diseases. Such research represents unfinished Report fellOw Allison Thorpe business of global relevance, work that the world can no longer afford to neglect. 11 According to the latest published data in 2012, infectious (including parasitic) diseases were together responsible for the death of more than 8.7 million people worldwide in 2008 (1). The majority of these deaths were of poor people living in low and middle- income countries, with many of the deaths Infectious diseases have occurring in children under five years of age. shaped societies, driven Given the sketchy data, misdiagnosis and conflict and spawned the under-detection that are typical of health marginalization of infected systems in impoverished areas, these num- individuals and communities bers are almost certainly underestimated.
    [Show full text]
  • Adaptive Designs in Clinical Trials: Why Use Them, and How to Run and Report Them Philip Pallmann1* , Alun W
    Pallmann et al. BMC Medicine (2018) 16:29 https://doi.org/10.1186/s12916-018-1017-7 CORRESPONDENCE Open Access Adaptive designs in clinical trials: why use them, and how to run and report them Philip Pallmann1* , Alun W. Bedding2, Babak Choodari-Oskooei3, Munyaradzi Dimairo4,LauraFlight5, Lisa V. Hampson1,6, Jane Holmes7, Adrian P. Mander8, Lang’o Odondi7, Matthew R. Sydes3,SofíaS.Villar8, James M. S. Wason8,9, Christopher J. Weir10, Graham M. Wheeler8,11, Christina Yap12 and Thomas Jaki1 Abstract Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial’s course in accordance with pre-specified rules. Trials with an adaptive design are often more efficient, informative and ethical than trials with a traditional fixed design since they often make better use of resources such as time and money, and might require fewer participants. Adaptive designs can be applied across all phases of clinical research, from early-phase dose escalation to confirmatory trials. The pace of the uptake of adaptive designs in clinical research, however, has remained well behind that of the statistical literature introducing new methods and highlighting their potential advantages. We speculate that one factor contributing to this is that the full range of adaptations available to trial designs, as well as their goals, advantages and limitations, remains unfamiliar to many parts of the clinical community. Additionally, the term adaptive design has been misleadingly used as an all-encompassing label to refer to certain methods that could be deemed controversial or that have been inadequately implemented. We believe that even if the planning and analysis of a trial is undertaken by an expert statistician, it is essential that the investigators understand the implications of using an adaptive design, for example, what the practical challenges are, what can (and cannot) be inferred from the results of such a trial, and how to report and communicate the results.
    [Show full text]
  • Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy
    Review Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy Yuxi Zhao and Lifeng Lin * Department of Statistics, Florida State University, Tallahassee, FL 32306, USA; [email protected] * Correspondence: [email protected] Abstract: Systematic reviews and meta-analyses have been increasingly used to pool research find- ings from multiple studies in medical sciences. The reliability of the synthesized evidence depends highly on the methodological quality of a systematic review and meta-analysis. In recent years, several tools have been developed to guide the reporting and evidence appraisal of systematic reviews and meta-analyses, and much statistical effort has been paid to improve their methodological quality. Nevertheless, many contemporary meta-analyses continue to employ conventional statis- tical methods, which may be suboptimal compared with several alternative methods available in the evidence synthesis literature. Based on a recent systematic review on COVID-19 in pregnancy, this article provides an overview of select good practices for performing meta-analyses from sta- tistical perspectives. Specifically, we suggest meta-analysts (1) providing sufficient information of included studies, (2) providing information for reproducibility of meta-analyses, (3) using appro- priate terminologies, (4) double-checking presented results, (5) considering alternative estimators of between-study variance, (6) considering alternative confidence intervals, (7) reporting predic- Citation: Zhao, Y.; Lin, L. Good tion intervals, (8) assessing small-study effects whenever possible, and (9) considering one-stage Statistical Practices for Contemporary methods. We use worked examples to illustrate these good practices. Relevant statistical code Meta-Analysis: Examples Based on a is also provided.
    [Show full text]
  • Short List of Commonly Used Acronyms in Clinical Research
    Short List of Commonly Used Acronyms in Clinical Research ACRP Association of Clinical Research Professionals AE Adverse Event ADR Adverse Drug Reaction AMA American Medical Association BAA Business Associate Agreement BIND Biological IND CA Coverage Analysis CAP College of American Pathologists CBCTN Community Based Clinical Trials Network CCRA Certified Clinical Research Associate (ACRP) CCRC Certified Clinical Research Coordinator (ACRP) CCRT Center for Clinical Research & Technology CCRP Certified Clinical Research Professional (SoCRA) CDA Confidential Disclosure Agreement CDC Center for Disease Control CFR Code of Federal Regulations CIRBI Center for IRB Intelligence CITI Collaborative Institutional Training Initiative CLIA Clinical Laboratory Improvement Amendments CME Continuing Medical Education CMS Central Management System COI Conflict of Interest CRA Clinical Research Associate CRC Clinical Research Coordinator CREC Continuing Research Education Credit CRF Case Report Form CRO Clinical Research Organization CTA Clinical Trial Agreement CTSC Clinical & Translational Science Collaborative CV Curriculum Vitae DCF Data Correction Form / Data Clarification Form DEA Drug Enforcement Agency (law enforcement division of FDA) DHHS Department of Health and Human Services DOS Date of Service DSMB or Data and Safety Monitoring Board (Plan or Committee) DSMP/C EAB Ethical Advisory Board (similar to IRB, used by other nations) EDC Electronic Data Capture FDA Food and Drug Administration FDA-482 Notice of Inspection FDA-483 Notice of Adverse
    [Show full text]